Rhythm
Journal Title: Generics and Biosimilars Initiative Journal - Year 2012, Vol 1, Issue 1
Abstract
Clinical biosimilar data should be accessible to all Calls are growing for biosimilar manufacturers to publish their data in the public domain, particularly when developing versions of monoclonal antibodies that are associated with potential survival benefits. One of GaBI Online’s readers totally agrees with this message. However, few others wonder why biosimilar producers must handle safety and efficacy data with transparency while the originator will have its data protected through temporary periods of exclusivity. Leaving aside economic reasons, are there any public health or access to information arguments that justify meaningful differences of treatment between both sets of data?
Authors and Affiliations
GaBI Journal Editor
Keywords
Related Articles
- EP ID EP355205
- DOI 10.5639/gabij.2012.0101.012
- Views 98
- Downloads 0
Biosimilars naming and prescribing policy in Australia
To the Editor: I wanted to bring to your attention the following paper which was published in Volume 2/Year 2013/Issue 3 of the Generics and Biosimilars Initiative Journal. The Perspective paper titled Licensing and pr...
Understanding the components of pharmaceutical expenditure—overview of pharmaceutical policies influencing expenditure across European countries
Aim: To explain the components of pharmaceutical expenditure and illustrate the strengths and limitations of this indicator. In particular, we explore policies applied in European countries that affect the price and volu...
Why bioequivalence and unconditional interchangeability of generic drugs are not the same
The patents for a number of cornerstone immunosuppressive drugs used in the field of solid organ transplantation have expired. Generic formulations are now available and several professional societies and individual phys...
Innovator companies should focus on innovations
Despite biopharmaceuticals having an enormous potential value for our health, they have also become a serious threat to our healthcare systems.
Complex molecules – current developments
The pharmacological activity and toxicity of non-biological complex drugs (NBCDs) depends on their complex structure and composition. The regulatory approach leading to the registration of such drugs and their follow-on...